IT AI in Oncology: Hype, Evidence, and the Threshold of Clinical Trust | Precision Signals Ep. 1

IT AI in Oncology: Hype, Evidence, and the Threshold of Clinical Trust

Precision Signals Ep. 1

What does it take for AI to move from technical innovation to real-world adoption in oncology?

In the first episode of Precision Signals, a new podcast from the CEO Roundtable on Cancer, Dr. Sean Khozin speaks with Dr. Cora Sternberg and Dr. Olivier Elemento - two leaders at the intersection of clinical trials, precision medicine, and computational biology.

Together, they unpack the central paradox of medical AI: why so many tools are technically validated, yet so few are clinically trusted. Topics include:

• Why randomized clinical trials—not just retrospective benchmarks—are essential for AI adoption
• The limitations of current training data and the risks of treating clinical guidelines as ground truth
• The evolving role of real-world data, EHRs, and multimodal inputs in building more adaptive AI systems
• What physicians actually need to trust and use AI in everyday cancer care

This is a candid conversation about evidence, trust, and what it will take to build AI that earns a place in the oncology clinic, grounded in insights from the participants’ recent review published in NEJM AI: https://ai.nejm.org/doi/abs/10.1056/AIra2401164​